MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Arcutis Biotherapeutics Inc

Closed

SectorHealthcare

14.66 -5.36

Overview

Share price change

24h

Current

Min

14.46

Max

15.71

Key metrics

By Trading Economics

Income

-14M

-25M

Sales

-5.5M

66M

Profit margin

-38.059

Employees

342

EBITDA

-14M

-19M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+37.53% upside

Dividends

By Dow Jones

Next Earnings

13 sie 2025

Market Stats

By TradingEconomics

Market Cap

79M

1.9B

Previous open

20.02

Previous close

14.66

News Sentiment

By Acuity

50%

50%

169 / 376 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 lip 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 lip 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 lip 2025, 21:04 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 lip 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 lip 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 lip 2025, 22:47 UTC

Acquisitions, Mergers, Takeovers

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 lip 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 lip 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 lip 2025, 22:43 UTC

Acquisitions, Mergers, Takeovers

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 lip 2025, 22:43 UTC

Acquisitions, Mergers, Takeovers

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 lip 2025, 22:40 UTC

Acquisitions, Mergers, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lip 2025, 22:40 UTC

Acquisitions, Mergers, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lip 2025, 22:30 UTC

Market Talk
Earnings

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 lip 2025, 22:20 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

17 lip 2025, 22:20 UTC

Market Talk
Earnings

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 lip 2025, 22:04 UTC

Market Talk
Earnings

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 lip 2025, 22:03 UTC

Acquisitions, Mergers, Takeovers

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 lip 2025, 21:58 UTC

Market Talk
Earnings

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 lip 2025, 21:57 UTC

Earnings

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lip 2025, 21:47 UTC

Earnings

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 lip 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 lip 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 lip 2025, 21:38 UTC

Acquisitions, Mergers, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 lip 2025, 21:22 UTC

Acquisitions, Mergers, Takeovers

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lip 2025, 21:05 UTC

Earnings

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lip 2025, 21:04 UTC

Acquisitions, Mergers, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 lip 2025, 21:02 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lip 2025, 20:59 UTC

Acquisitions, Mergers, Takeovers

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 lip 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

17 lip 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Arcutis Biotherapeutics Inc Forecast

Price Target

By TipRanks

37.53% upside

12 Months Forecast

Average 21.29 USD  37.53%

High 29 USD

Low 19 USD

Based on 7 Wall Street analysts offering 12 month price targets forArcutis Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

12.42 / 14.93Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

169 / 376 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.